Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Drugs Office Take Two: FDA To Elevate Division Through CDER Revamp

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA proposal for Office of OTC Drug Products would oversee two divisions for monographed, NDA-approved products. Former home of OTC division, ODE V, would be eliminated under CDER reorganization.

You may also be interested in...



FDA Reorganization Of New Drug Office Would Split Neuropharmaceutical Division

Neurology and psychiatry drugs would be reviewed in separate divisions under the proposed restructuring. The reorganization, which aims to group products by therapeutic indications and integrate the review of biologics and drugs, would eliminate ODE V.

NDAC Approach To OTC Switches Highlighted At Corticosteroid Meeting

Panel review provides examples of different attitudes toward switches between OTC experts, other category-specific prescribers.

Plan B Decision Expected In Coming Weeks, Barr CEO Says

Downey says Rx sales of approximately $20 mil. have restricted availability of the emergency contraceptive at pharmacies across the country.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel